translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
MAC (MAI) Treatment Trial at NIH: Sparfloxacin, Azithromycin

June 5, 1992
AIDS Treatment News (06/05/92) No. 152, P. 7

AIDS patients with MAC bacteremia who are in a relatively stable condition and able to travel to the National Institutes of Health in Bethesda, Md., may qualify for a trail which randomly assigns sparfloxacin, azithromycin, or the combination of these drugs for MAC treatment. All participants receive oral medication with no placebo involved in the trial. Study visits will be weekly for one month, every two weeks for the next eight weeks, and then monthly. Participants will be monitored as long as possible. In addition, those who fail any treatment arm may obtain a four-drug combination consisting of sparfloxacin, azithromycin, clofazimine, and ethambutol. Part of the purpose of the study is to test this method.